RPRX logo

Royalty Pharma plc (RPRX) Selling, General & Administrative Expenses

Annual SG&A:

$0.00-$249.75M(-100.00%)
December 31, 2024

Summary

  • As of today, RPRX annual SG&A is $0.00, with the most recent change of -$249.75 million (-100.00%) on December 31, 2024.
  • During the last 3 years, RPRX annual SG&A has fallen by -$182.83 million (-100.00%).
  • RPRX annual SG&A is now -100.00% below its all-time high of $249.75 million, reached on December 31, 2023.

Performance

RPRX SG&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRPRXincome statement metrics

Quarterly SG&A:

$179.77M+$69.06M(+62.39%)
June 30, 2025

Summary

  • As of today, RPRX quarterly SG&A is $179.77 million, with the most recent change of +$69.06 million (+62.39%) on June 30, 2025.
  • Over the past year, RPRX quarterly SG&A has increased by +$125.06 million (+228.60%).
  • RPRX quarterly SG&A is now at all-time high.

Performance

RPRX Quarterly SG&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRPRXincome statement metrics

TTM SG&A:

$10.31B-$155.50M(-1.49%)
June 30, 2025

Summary

  • As of today, RPRX TTM SG&A is $10.31 billion, with the most recent change of -$155.50 million (-1.49%) on June 30, 2025.
  • Over the past year, RPRX TTM SG&A has increased by +$10.08 billion (+4408.17%).
  • RPRX TTM SG&A is now -1.49% below its all-time high of $10.47 billion.

Performance

RPRX TTM SG&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRPRXincome statement metrics

Selling, General & Administrative Expenses Formula

SG&A = Total Operating Expenses - Cost of Goods Sold - Research & Development

RPRX Selling, General & Administrative Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-100.0%+228.6%+4408.2%
3Y3 Years-100.0%+246.8%+5105.5%
5Y5 Years-100.0%+320.0%+6568.8%

RPRX Selling, General & Administrative Expenses Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-100.0%at lowat high+277.4%-1.5%+20.4%
5Y5-Year-100.0%at lowat high+316.6%-1.5%+42.8%
All-TimeAll-Time-100.0%at lowat high+679.5%-1.5%+265.1%

RPRX Selling, General & Administrative Expenses History

DateAnnualQuarterlyTTM
Jun 2025
-
$179.77M(+62.4%)
$414.79M(+43.2%)
Mar 2025
-
$110.70M(+63.8%)
$289.72M(+22.4%)
Dec 2024
$0.00(-100.0%)
$67.59M(+19.2%)
$236.67M(+3.7%)
Sep 2024
-
$56.72M(+3.7%)
$228.26M(-0.2%)
Jun 2024
-
$54.71M(-5.1%)
$228.78M(+3.2%)
Mar 2024
-
$57.65M(-2.6%)
$221.71M(-11.2%)
Dec 2023
$249.75M(+9.9%)
$59.19M(+3.4%)
$249.75M(-5.3%)
Sep 2023
-
$57.23M(+20.2%)
$263.79M(+2.5%)
Jun 2023
-
$47.63M(-44.4%)
$257.25M(-1.6%)
Mar 2023
-
$85.69M(+17.0%)
$261.46M(+15.0%)
Dec 2022
$227.30M(+24.3%)
$73.23M(+44.5%)
$227.30M(+13.5%)
Sep 2022
-
$50.69M(-2.2%)
$200.24M(+1.1%)
Jun 2022
-
$51.84M(+0.6%)
$198.13M(+3.6%)
Mar 2022
-
$51.54M(+11.7%)
$191.21M(+4.6%)
Dec 2021
$182.83M
$46.16M(-5.0%)
$182.83M(-2.1%)
DateAnnualQuarterlyTTM
Sep 2021
-
$48.59M(+8.2%)
$186.78M(-1.1%)
Jun 2021
-
$44.92M(+4.1%)
$188.93M(+1.1%)
Mar 2021
-
$43.16M(-13.9%)
$186.81M(+2.8%)
Dec 2020
$181.72M(+75.7%)
$50.12M(-1.2%)
$181.72M(+17.5%)
Sep 2020
-
$50.73M(+18.5%)
$154.66M(+19.4%)
Jun 2020
-
$42.80M(+12.4%)
$129.53M(+10.6%)
Mar 2020
-
$38.06M(+65.1%)
$117.08M(+13.2%)
Dec 2019
$103.44M(+67.1%)
$23.06M(-9.9%)
$103.44M(+28.7%)
Sep 2019
-
$25.60M(-15.6%)
$80.38M(+46.7%)
Jun 2019
-
$30.35M(+24.2%)
$54.77M(+124.2%)
Mar 2019
-
$24.43M
$24.43M
Dec 2018
$61.91M(-41.8%)
-
-
Dec 2017
$106.44M(+53.1%)
-
-
Dec 2016
$69.51M(-42.7%)
-
-
Dec 2015
$121.42M
-
-

FAQ

  • What is Royalty Pharma plc annual SG&A?
  • What is the all-time high annual SG&A for Royalty Pharma plc?
  • What is Royalty Pharma plc annual SG&A year-on-year change?
  • What is Royalty Pharma plc quarterly SG&A?
  • What is the all-time high quarterly SG&A for Royalty Pharma plc?
  • What is Royalty Pharma plc quarterly SG&A year-on-year change?
  • What is Royalty Pharma plc TTM SG&A?
  • What is the all-time high TTM SG&A for Royalty Pharma plc?
  • What is Royalty Pharma plc TTM SG&A year-on-year change?

What is Royalty Pharma plc annual SG&A?

The current annual SG&A of RPRX is $0.00

What is the all-time high annual SG&A for Royalty Pharma plc?

Royalty Pharma plc all-time high annual SG&A is $249.75M

What is Royalty Pharma plc annual SG&A year-on-year change?

Over the past year, RPRX annual SG&A has changed by -$249.75M (-100.00%)

What is Royalty Pharma plc quarterly SG&A?

The current quarterly SG&A of RPRX is $179.77M

What is the all-time high quarterly SG&A for Royalty Pharma plc?

Royalty Pharma plc all-time high quarterly SG&A is $179.77M

What is Royalty Pharma plc quarterly SG&A year-on-year change?

Over the past year, RPRX quarterly SG&A has changed by +$125.06M (+228.60%)

What is Royalty Pharma plc TTM SG&A?

The current TTM SG&A of RPRX is $10.31B

What is the all-time high TTM SG&A for Royalty Pharma plc?

Royalty Pharma plc all-time high TTM SG&A is $10.47B

What is Royalty Pharma plc TTM SG&A year-on-year change?

Over the past year, RPRX TTM SG&A has changed by +$10.08B (+4408.17%)
On this page